Dr. Higano on Radium-223 for mCRPC

Celestia S. Higano
Published: Monday, Mar 16, 2015



Celestia S. Higano, MD, FACP, professor of medicine and urology, University of Washington, discusses radium-223 chloride and its efficacy for patients with metastatic castration-resistant prostate cancer (mCRPC).

Higano says radium-223 (Xofigo), a radium isotope approved by the FDA to treat mCRPC, is unique from other therapies in cancer overall. Results from a phase III study showed that patients who received radium-223 had higher overall survival (OS) compared to patients who did not receive the therapy.

Radium-223 can also benefit patients who may have skeletal metastases, fractures, or require external beam radiation, Higano says.

Radium-223 is an exciting new tool and researchers are exploring how it can be used with other novel therapies that have been developed in the last few years.



Celestia S. Higano, MD, FACP, professor of medicine and urology, University of Washington, discusses radium-223 chloride and its efficacy for patients with metastatic castration-resistant prostate cancer (mCRPC).

Higano says radium-223 (Xofigo), a radium isotope approved by the FDA to treat mCRPC, is unique from other therapies in cancer overall. Results from a phase III study showed that patients who received radium-223 had higher overall survival (OS) compared to patients who did not receive the therapy.

Radium-223 can also benefit patients who may have skeletal metastases, fractures, or require external beam radiation, Higano says.

Radium-223 is an exciting new tool and researchers are exploring how it can be used with other novel therapies that have been developed in the last few years.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x